Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel Positron Emission Tomography (PET) Radiotracers in Castration-Resistant Prostate Cancer

NCT02813226 is registered in ClinicalTrials.gov with Ontario Clinical Oncology Group (OCOG) as lead sponsor.

NCT NCT02813226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02813226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel Positron Emission Tomography (PET) Radiotracers in Castration-Resistant Prostate Cancer
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Phase
Not applicable
Overall status
Completed
Start date
February 16, 2017
Completion date
December 17, 2021
Enrollment
36 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer